Form EFFECT Lyell Immunopharma, Inc.
Tweet
Share
E-mail| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | December 15, 2025 4:00 P.M. |
| Form: | S-3 | ||||||
| |||||||
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients
- Golden State Dermatology Expands into Colorado with Acquisition of Summit Dermatology
- Natural Grocers® Hosts Virtual Hiring Event for Los Alamos, New Mexico Location on August 27, 2026
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
